1 00:00:00,160 --> 00:00:03,000 Speaker 1: Some good news this morning for keV prostate cancer patients. 2 00:00:03,040 --> 00:00:06,520 Speaker 1: Results from a study from twelve leading UK cancer centers 3 00:00:06,640 --> 00:00:09,600 Speaker 1: found men with early signs of prostate cancer who undergo 4 00:00:09,720 --> 00:00:14,040 Speaker 1: a highly targeted type of radiotherapy reduce the risk of 5 00:00:14,080 --> 00:00:19,280 Speaker 1: two major long term side effects in continence and sexual dysfunction, 6 00:00:19,640 --> 00:00:22,720 Speaker 1: but also cuts the treatment time down from about twenty 7 00:00:22,800 --> 00:00:26,040 Speaker 1: visits to just five. Four Thousand men are diagnosed with 8 00:00:26,079 --> 00:00:29,280 Speaker 1: prostate cancer in New Zealand each year. Giuseppe Sasso is 9 00:00:29,320 --> 00:00:31,840 Speaker 1: a radiation oncologist and is with us Live this morning. 10 00:00:31,880 --> 00:00:34,760 Speaker 2: Good morning, Good morning cure everyone. 11 00:00:34,800 --> 00:00:37,559 Speaker 1: How are you yeah, really well? Thank you? What exactly 12 00:00:37,720 --> 00:00:41,559 Speaker 1: is this? Can you describe how it works? This targeted radiotherapy? 13 00:00:43,159 --> 00:00:47,560 Speaker 2: Yes, so it's a it's a new form of radiotherapy 14 00:00:47,640 --> 00:00:52,960 Speaker 2: that is called stereotactica blative radiotherapy also SBRT or SABER, 15 00:00:53,560 --> 00:00:57,600 Speaker 2: and instead of delivering a radiation over a long course 16 00:00:57,640 --> 00:01:04,520 Speaker 2: of treatment twenty appointments five times a week over four weeks, 17 00:01:04,760 --> 00:01:09,319 Speaker 2: it delivers treatment in only five appointments of about twenty 18 00:01:09,360 --> 00:01:15,000 Speaker 2: minutes thirty minutes each. This new form of radio therapy 19 00:01:15,640 --> 00:01:19,160 Speaker 2: can be delivered with either conventional liner accelerators, so the 20 00:01:19,240 --> 00:01:21,640 Speaker 2: historical machine. They have been used for many years to 21 00:01:21,680 --> 00:01:26,480 Speaker 2: treat patients with radiotherapy or otherwise with a new form 22 00:01:26,560 --> 00:01:32,760 Speaker 2: of linear accelerators that are called capable of motion management. 23 00:01:33,200 --> 00:01:36,399 Speaker 2: One of them is, for instance, the cyber knife, which 24 00:01:36,440 --> 00:01:39,960 Speaker 2: is a machine that is capable of tracking the motion 25 00:01:40,120 --> 00:01:42,800 Speaker 2: of the target during the delivery of the radiation. 26 00:01:43,800 --> 00:01:45,679 Speaker 1: So it's like, how does it do that? Is it 27 00:01:45,800 --> 00:01:47,840 Speaker 1: like a laser or something that tracks. 28 00:01:47,520 --> 00:01:54,640 Speaker 2: Have The machine has the radio therapy device mounted on 29 00:01:54,680 --> 00:02:01,120 Speaker 2: a highly precise robotic unit which basically is capable of 30 00:02:01,440 --> 00:02:05,640 Speaker 2: seeing the motion of the prostate because the process has 31 00:02:05,680 --> 00:02:08,919 Speaker 2: some little beads, little seeds of golden that are being 32 00:02:08,919 --> 00:02:13,639 Speaker 2: inserted by urologists prior to the delivery of the treatment, 33 00:02:13,960 --> 00:02:18,239 Speaker 2: and the machine can actually see those beads in three 34 00:02:18,280 --> 00:02:22,280 Speaker 2: dimensions and follow them with some limited accuracy, so. 35 00:02:22,200 --> 00:02:24,920 Speaker 1: It can target it way bit of targeting. And what 36 00:02:24,960 --> 00:02:28,320 Speaker 1: does this mean? Obviously it could mean shorter you know 37 00:02:28,520 --> 00:02:32,040 Speaker 1: time spent and going to appointments and stuff like that, 38 00:02:32,240 --> 00:02:35,160 Speaker 1: But what does it mean for you know, survival and health. 39 00:02:37,360 --> 00:02:40,720 Speaker 2: We're known for a very long time that both surgery 40 00:02:40,760 --> 00:02:43,680 Speaker 2: prostrotect them in the removal of the prospects and radiotherapy 41 00:02:44,160 --> 00:02:48,360 Speaker 2: have very very high rate of survival and control of 42 00:02:48,440 --> 00:02:53,400 Speaker 2: prospect cancer, especially when this is quoted at a very 43 00:02:53,440 --> 00:02:59,920 Speaker 2: early stage of disease. In terms of this recent data, 44 00:03:00,639 --> 00:03:03,519 Speaker 2: what we know now is that the most the more 45 00:03:03,600 --> 00:03:08,440 Speaker 2: targeted radiotherapy with the technique that have just explained, the 46 00:03:08,480 --> 00:03:12,360 Speaker 2: stereotatic ablative radiation seems to be a little bit better 47 00:03:12,680 --> 00:03:19,640 Speaker 2: than conventional radiotherapy in controlling prospect cancer five years. Of course, 48 00:03:19,680 --> 00:03:23,720 Speaker 2: we will wait for data at ten years and fifteen years, 49 00:03:23,800 --> 00:03:29,440 Speaker 2: but it is very exciting for patients and for radiation 50 00:03:29,560 --> 00:03:34,840 Speaker 2: oncologists and the urology community to know that districtment is 51 00:03:34,840 --> 00:03:39,840 Speaker 2: so effective and it also it appears that when delivered 52 00:03:39,960 --> 00:03:43,880 Speaker 2: so precisely, the rate of side effects is incredibly low, 53 00:03:44,160 --> 00:03:46,840 Speaker 2: with very very low risk of severe complications. 54 00:03:46,880 --> 00:03:49,480 Speaker 1: Yeah, which and that those particular complications are the ones 55 00:03:49,520 --> 00:03:52,000 Speaker 1: that men worry about, you know, your incontinence and your 56 00:03:52,040 --> 00:03:54,440 Speaker 1: sexual dysfunction. Jusepe. So, so thank you very much for 57 00:03:54,440 --> 00:03:56,760 Speaker 1: your time. Radiation Oncologists, some good news this morning. 58 00:03:57,720 --> 00:04:00,680 Speaker 2: For more fam earlier edition with Ryan Bridge, listen live 59 00:04:00,800 --> 00:04:03,840 Speaker 2: to news Talks it'd be from five am weekdays, or 60 00:04:03,880 --> 00:04:05,800 Speaker 2: follow the podcast on iHeartRadio.